CN1223608C - 与半胱天冬蛋白酶－8相互作用的蛋白 - Google Patents

与半胱天冬蛋白酶－8相互作用的蛋白 Download PDF

Info

Publication number
CN1223608C
CN1223608C CNB998053627A CN99805362A CN1223608C CN 1223608 C CN1223608 C CN 1223608C CN B998053627 A CNB998053627 A CN B998053627A CN 99805362 A CN99805362 A CN 99805362A CN 1223608 C CN1223608 C CN 1223608C
Authority
CN
China
Prior art keywords
leu
pro
caspase
ala
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998053627A
Other languages
English (en)
Chinese (zh)
Other versions
CN1298411A (zh
Inventor
D·沃勒克
M·舒赫曼
T·冈察洛夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL12772198A external-priority patent/IL127721A0/xx
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN1298411A publication Critical patent/CN1298411A/zh
Application granted granted Critical
Publication of CN1223608C publication Critical patent/CN1223608C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01033—N-Acetylglucosamine deacetylase (3.5.1.33)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
CNB998053627A 1998-12-24 1999-12-23 与半胱天冬蛋白酶－8相互作用的蛋白 Expired - Fee Related CN1223608C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IL12772198A IL127721A0 (en) 1998-12-24 1998-12-24 Caspase-8 interacting proteins
IL127721 1998-12-24
IL132105 1999-09-28
IL13210599A IL132105A0 (en) 1998-12-24 1999-09-28 Caspase-8 interacting proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100563830A Division CN1603342A (zh) 1998-12-24 1999-12-23 与半胱天冬蛋白酶－8相互作用的蛋白

Publications (2)

Publication Number Publication Date
CN1298411A CN1298411A (zh) 2001-06-06
CN1223608C true CN1223608C (zh) 2005-10-19

Family

ID=26323761

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB998053627A Expired - Fee Related CN1223608C (zh) 1998-12-24 1999-12-23 与半胱天冬蛋白酶－8相互作用的蛋白
CNA2004100563830A Pending CN1603342A (zh) 1998-12-24 1999-12-23 与半胱天冬蛋白酶－8相互作用的蛋白

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100563830A Pending CN1603342A (zh) 1998-12-24 1999-12-23 与半胱天冬蛋白酶－8相互作用的蛋白

Country Status (19)

Country Link
US (3) US6762283B1 (enExample)
EP (1) EP1058691A1 (enExample)
JP (1) JP2002536965A (enExample)
KR (2) KR100646075B1 (enExample)
CN (2) CN1223608C (enExample)
AR (1) AR029321A1 (enExample)
AU (1) AU780585B2 (enExample)
BG (2) BG65375B1 (enExample)
BR (1) BR9909252A (enExample)
CA (1) CA2321672A1 (enExample)
EA (2) EA007273B1 (enExample)
EE (1) EE200000487A (enExample)
HU (1) HUP0100671A3 (enExample)
IL (3) IL132105A0 (enExample)
NO (1) NO20004167L (enExample)
NZ (1) NZ506477A (enExample)
PL (1) PL350181A1 (enExample)
SK (1) SK12682000A3 (enExample)
WO (1) WO2000039160A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694485A (zh) * 2015-02-13 2015-06-10 广西壮族自治区兽医研究所 Z-ietd-fmk在提高prrsv体外培养滴度方面的应用及其方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20040049845A (ko) * 2001-09-04 2004-06-12 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 카스파제-8 결합 단백질, 이의 제조 및 용도
US20040072770A1 (en) * 2002-07-03 2004-04-15 Besterman Jeffrey M. Methods for specifically inhibiting histone deacetylase-7 and 8
IL158599A0 (en) * 2003-10-26 2004-05-12 Yeda Res & Dev Methods of modulating hematopoiesis
EP2155691B1 (en) * 2007-02-23 2016-01-13 Yeda Research and Development Co. Ltd. Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
WO2010006177A2 (en) * 2008-07-10 2010-01-14 Dana-Farber Cancer Institute, Inc. Muc1, caspase-8,and ded-containing proteins
ES2746529T3 (es) 2014-09-04 2020-03-06 Memorial Sloan Kettering Cancer Center Terapia génica de globina para tratar hemoglobinopatías
CN106146665B (zh) * 2016-08-31 2019-08-09 中国农业科学院植物保护研究所 一种用于制备针对甜菜夜蛾caspase-5大亚基的抗体的方法
IL269328B2 (en) * 2017-03-16 2023-11-01 Immunwork Inc Binding units and molecules containing them

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
IL94039A (en) * 1989-08-06 2006-09-05 Yeda Res & Dev Antibodies to tbp - 1 and their use
JPH0625292A (ja) * 1990-10-31 1994-02-01 Mitsui Toatsu Chem Inc タンパク質及びその遺伝子
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU3665893A (en) * 1992-02-12 1993-09-03 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
US5364503A (en) 1992-02-20 1994-11-15 Macmillan Bloedel Limited Nitric oxide treatment for ozone bleaching
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
IL104355A (en) * 1993-01-10 2006-08-20 Yeda Res & Dev Tnf receptor promoter
IL109633A (en) * 1994-05-11 2005-05-17 Yeda Res & Dev Tnf receptor promoter
JP2002514903A (ja) * 1996-06-17 2002-05-21 ジンザイム コーポレイション 新規のヒト第１６染色体遺伝子、組成物、それを作製および使用する方法
US6242569B1 (en) * 1997-02-05 2001-06-05 Tularik, Inc. Regulators of apoptosis
JP2003500002A (ja) * 1998-05-29 2003-01-07 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒトヒドロラーゼ相同体：ｎ−末端アスパラギンアミドヒドロラーゼ、グリコシルヒドロラーゼ、グルコヒドロラーゼ、ビオチニダーゼ及びｎ−アセチルグルコサミン６−ｐデアセチラーゼ
US6326354B1 (en) * 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
CA2350415A1 (en) * 1998-11-18 2000-05-25 Incyte Pharmaceuticals, Inc. Inflammation-associated genes
EP1002900A1 (de) 1998-11-18 2000-05-24 SP Beton GmbH & Co. KG Verkehrsflächen-Bodenbelag mit Bodenbelagelementen aus Kunststeinmaterial

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104694485A (zh) * 2015-02-13 2015-06-10 广西壮族自治区兽医研究所 Z-ietd-fmk在提高prrsv体外培养滴度方面的应用及其方法

Also Published As

Publication number Publication date
US7339047B2 (en) 2008-03-04
IL138025A (en) 2007-08-19
EA200401390A1 (ru) 2005-02-24
NO20004167L (no) 2000-10-19
SK12682000A3 (sk) 2001-03-12
AU1795000A (en) 2000-07-31
KR100646075B1 (ko) 2006-11-15
US6762283B1 (en) 2004-07-13
CN1603342A (zh) 2005-04-06
AR029321A1 (es) 2003-06-25
PL350181A1 (en) 2002-11-18
EE200000487A (et) 2002-02-15
EA007273B1 (ru) 2006-08-25
EA005853B1 (ru) 2005-06-30
NO20004167D0 (no) 2000-08-21
HUP0100671A3 (en) 2006-04-28
US20040229260A1 (en) 2004-11-18
IL178921A0 (en) 2007-03-08
BG109904A (bg) 2008-01-31
US20080139476A1 (en) 2008-06-12
IL132105A0 (en) 2001-03-19
EA200000875A1 (ru) 2001-10-22
WO2000039160A3 (enExample) 2001-08-23
CA2321672A1 (en) 2000-07-06
KR20010041250A (ko) 2001-05-15
BG104707A (en) 2001-04-30
KR20060090770A (ko) 2006-08-16
CN1298411A (zh) 2001-06-06
JP2002536965A (ja) 2002-11-05
BG65375B1 (bg) 2008-04-30
WO2000039160A2 (en) 2000-07-06
KR100646074B1 (ko) 2006-11-13
BR9909252A (pt) 2000-11-28
HK1037197A1 (en) 2002-02-01
NZ506477A (en) 2003-08-29
AU780585B2 (en) 2005-04-07
HUP0100671A2 (hu) 2001-06-28
EP1058691A1 (en) 2000-12-13

Similar Documents

Publication Publication Date Title
CN1173033C (zh) Tnf/ngf超家族受体和可溶性寡聚tnf/ngf超家族受体的调节剂
CN1197966C (zh) 肿瘤坏死因子受体相关因子的调节剂、及其制备和用途
CN1390232A (zh) 人β分泌酶、抑制剂、其组合物和用途
CN1229499C (zh) 磷酸二酯酶8a
CN1091469A (zh) Ptp 1d：一种新蛋白质酪氨酸磷酸
CN1105725C (zh) Fas/ap01受体功能的调节物
CN1091139A (zh) 蛋白质酪氨酸磷酸酶的ptp-d亚家族
CN1223608C (zh) 与半胱天冬蛋白酶－8相互作用的蛋白
CN1189564C (zh) Tnf/ngf受体家族中受体功能的调节剂
CN1630664A (zh) 胱冬酶－8结合蛋白及其制备和使用
CN1232641C (zh) Tnf/ngf受体家族和其它蛋白质的受体的功能的调节剂
CN1259165A (zh) 胞内发炎、细胞死亡和细胞存活通道的调节剂
CN1148446C (zh) 与mort-1和mach结合的多肽及其dna序列、生产方法、药物组合物和用途
CN1384878A (zh) Iren蛋白,其制备和应用
CN1286973C (zh) 一种组蛋白甲基转移酶及其制备方法
CN1717485A (zh) γ分泌酶的可溶性NOTCH－型底物和使用所述底物的方法和组合物
HK1072266A (en) Caspase-8 interacting proteins
HK1037197B (en) Caspase-8 interacting proteins
CN1169954C (zh) 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸
CN1599755A (zh) 抗天冬氨酸特异半胱氨酸蛋白酶－8的抗体,其制备方法及应用
CN1243830C (zh) 小鼠cxc趋化因子受体
HK1073472A (en) A caspase-8 binding protein, its preparation and use
HK1018910B (en) Modulators of the receptor associated factor(traf), their preparation and use
CN1169956C (zh) 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸
CN1169957C (zh) 编码具有抑制癌细胞生长功能的人蛋白的多核苷酸

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee